1. Tritiation of arecoline hydrochloride by catalytic exchange in aqueous media (done by The Radiochemical Centre) gave arecaidine hydrochloride of high specific radioactivity; this on treatment with diazomethane gave [3H] arecoline, which was oxidized with peroxyacetic acid to [3H] arecoline 1-oxide. 2. Arecoline 1-oxide gave arecaidine 1-oxide on acid hydrolysis and 1,2-dihydro-1-methylnicotinic acid methyl ester on thermal decomposition. 3.
[3H]Arecoline hydrochloride was metabolized in the rat into the 3H-labelled derivatives of arecoline 1-oxide, arecaidine 1-oxide, arecaidine, N-acetyl-S-(3-carboxy-1-methylpiperid-4-yl)-L-cysteine and an unidentified metabolite; some unchanged arecoline was also excreted.
[3H]Arecoline 1-oxide gave the same metabolities, but in different amounts. 4. The possible relevance of these findings to betel-nut oarcinogenesis is discussed.
The chewing of betel-nut preparations is a widespread Oriental habit which often spans the lifetime of the chewer and produces euphoria, addiction, dizziness, sweating, excessive salivation and a sensation of tightness in the throat. Various concoctions of the nut or of other parts of the areca palm are, or have been reputedly, used as treatment for diarrhoea, intestinal worms and other gastrointestinal disorders, gonorrhoea, ailments of vision, fever, dysentery, hysteria, schizophrenia, headaches, dental disorders, octopus bites and elephant diseases and as an abortifacient (Burkhill, 1935; Goswami & Ahmed, 1956 ; Arai & Nakayama, 1952) . There is some dispute as to whether this apparent panacea is associated with submucous fibrosis of the buccal cavity (For: Paymaster, 1962; Pindborg, 1965; Pindborg, Poulsen & Zachariah, 1967 . Against: Khanolkar, 1944; Balendra, 1949; Tennekoon & Bartlett, 1969) , but it is generally agreed that there is a parallelism between the prevalence of the betel-chewing habit and the incidence of cancers of the oropharynx (Muir & Kirk, 1960; Muir, 1967; Schonland & Bradshaw, 1969) . The composition ofthe quid shows regional and local variations, but the essential ingredients are the dried areca nut (Areca catechu L.) and lime with or without tobacco; the mixture is wrapped in the mature leaves of the betel vine (Piper betel). The cancers may be due to the combined action of the ingredients of the quid, or of the nuts and lime (Schonland & Bradshaw, 1969) or of the alkaloids of the nut (Boyland, 1968) . The active principle of the nut is arecoline (1,2,5,6-tetrahydro-1-methylnicotinic acid methyl ester; I, Scheme 1) which may comprise up to 0.8% by weight of the ripe nut (Goswami & Ahmed, 1956 ). Arecoline is a cathartic and vermifuge which exerts cholinergic, sialogogic, diaphoretic, parasympathomimetic and other effects similar to those produced by pilocarpine, muscarine and nicotine; it is probably the active principle, since the other betel-nut alkaloids do not show these effects or do so to a lesser extent (Burkhill, 1935; von Euler & Domeij, 1945; Goswami & Ahmed, 1956; Muir & Kirk, 1960; Pfeiffer, Beck & Goldstein, 1967; Nieschulz & Schmersahl, 1968; Boyland & Nery, 1969) . This work describes the metabolic interconversion of arecoline and arecoline 1-oxide in the rat.
MATERIALS AND METHODS
Measurement of radioactivity. This was done with a Packard Tri-Carb model 3375 liquid-scintillation spectrometer and values represent counts at least 50% above background, corrected for quenching by the addition of an internal standard. Paper strips cut off chromatograms or silica gel scraped off t.l.c. plates were assayed for radioactivity in glass phials containing lOml of scintillation fluid consisting of a solution of naphthalene (80g), 2,5-diphenyloxazole (5g) and 1,4-bis-(4-methyl-5-phenyloxazol-2-yl)benzene (.O5g) in a mixture of toluene (385 ml), dioxan (385 ml) and methanol (230 ml). Nucleic acids and proteins isolated from livers and acetone-dried powders were assayed as follows. DNA (2-5mg) was hydrolysed for 16h at 370C in aq. 0.1% (w/v) deoxy-R. NERY ribonuclease I solution (0.5ml; 75000 units), and RNA similarly in aq. 0.1% (w/v) ribonuclease solution (0.5ml; 50000 units) and proteins and acetone-dried powders (2-5 mg) were dissolved in tetraethylammonium hydroxide solution (1.0 ml); scintillation fluid ( 10 ml) was added to each mixture and the radioactivity determined.
Metabolic experiments.
[3H]Arecoline hydrochloride (sp. radioactivity, 1.72 Ci/mol) was administered by gavage to 6-week-old female Chester Beatty rats as an aq. 1% (w/v) solution (dose, 50mg/kg body wt.). The animals, which were starved for 8h before and for the duration of the experiments, were housed in polythene cages lined with two sheets of Whatman 3MM chromatography paper held in position with glass rods. Water was available ad lib. Preparation of acetone-dried powders of tissues and isolation of liver nucleic acids and proteins. Experimental animals were killed by cervical dislocation and freshly excised tissues were homogenized in 10vol. of acetone in an Ultra-Turrax homogenizer with a Teflon pestle. The homogenate was filtered and the residue washed with acetone until the final washing contained no radioactivity. DNA, RNA and proteins were isolated from freshly excised livers by the method of Kirby (1956) as modified by Brookes & Lawley (1965) , but the original method was used to remove polysaccharides. DNA was deproteinized by the detergent-salt procedure of Kay, Simmons & Dounce (1952) ; RNA was further purified by the Kirby (1956) phenol method and protein by repeated precipitations with acetone from solution in aq. 5% (w/v) NaCl until the final supernatant contained no residual radioactivity after evaporation.
Chromatography. Whatman no. 1 chromatography paper (unless otherwise stated) was used for overnight downward development in the following solvent systems: (a) butan-l-ol-propan-l-ol-aq. 2M-NH3 (2:1:1, by vol.) and (b) butan-l-ol-acetic acid-water (12:3:5, by vol.); and for ascending chromatography in (c) methanol-6M-HCI (7:3, v/v). For t.l.c., glass plates were coated with films (0.25 mm thick) of silica gel G (E. Merck A.-G., Darmstadt, Germany) and the chromatograms were developed in (d) ethanol-light petroleum (b.p.40-60°C)-2m-NH3 (6:1:1, by vol.) and (e) ethanol-acetic acid-water (1:1:8, by vol.). For the detection of compounds on chromatograms, other than by radioactivity assays, the following reagents were used: (i) ammoniacal aq. 2% (w/v) AgNO3; (ii) 0.1M-K2Cr2O7-acetic acid (1:1, v/v) followed by 0.1M-AgNO3; (iii) aq. 5% (w/v) KBiI4-10M- HCI (200:1, v/v) (Bartley, 1954) ; (iv) sodium amminoprusside (Boyland & Nery, 1965) and (v) 0.2M-NH2OH [made by adding a solution of NH2OH,HCI (1.38g) in methanol (50ml) to a similar solution of KOH (l.g) at 0°C immediately before use] followed by heating the chromatograms at 60°C for 10min and spraying with ethanolic 1% (w/v) v/v) .
N -Acetyl -S -(3 -carboxy -1 -methylpiperid -4 -yl) -Lcysteine (V, Scheme 1) gave a brown spot with reagent (ii); 1-methylpiperidines (I-VII) gave faint pink to red spots with reagent (iii); arecoline (I) and arecaidine (II) reduced reagent (i) after 3-4h; methyl esters (I, III, VI and VII) gave red to purple spots with reagent (v); arecoline N-oxide (III) and 3,4-epoxy-1,2,5,6-tetrahydro-1-methylnicotinic acid methyl ester 1-oxide (VII) gave purple spots with reagent (iv).
Chemicals. Arecoline and ribonuclease A were purchased from Sigma Chemical Co., St Louis, Mo., U.S.A.; N-acetyl-L-cysteine was purchased from British Drug Houses Ltd., Poole, Dorset, U.K., and deoxyribonuclease I (D) from Worthington Biochemical Corp., Freehold, N.J., U.S.A. Arecaidine and arecaidine hydrochloride were prepared as described by Boyland & Nery (1969) .
[3H]1,2,5,6-Tetrahydro-l-methylnicotinic acid (arecaidine, II, Scheme 1). Arecoline hydrochloride (2g) was tritiated by catalytic exchange in aqueous media and the mixture freed from catalyst. This was performed by
The Radiochemical Centre, Amersham, Bucks., U.K. The sample as received contained 4.5 Ci and examination by chromatography in solvent system (d) showed that it contained mainly arecaidine, i.e. the ester had been converted into the free acid either by catalytic reduction or by hydrolysis. The solution was neutralized with solid Na2CO3, evaporated in vacuo and the residue extracted with hot methanol (3 x 30 ml). The extracts were combined and acidified to pH2 with lOm-HCI, evaporated in vacuo and the residue was recrystallized from aq. 80% (v/v) ethanol to yield colourless plates of [3H]arecaidine hydrochloride (1.2g; sp. radioactivity, 301 Ci/mol; 2.04 Ci or 46% of radioactivity received), m.p. and mixed m.p. with the unlabelled compound 265°C (decomp). Chromatography in solvents (a), (b), (d) and (e) showed that the compound was indistinguishable from arecaidine hydrochloride.
[3H]1,2,5,6-Tetrahydro-1-methylnicotinic acid methyl ester (arecoline, I, Scheme 1). A solution of [3H]arecaidine hydrochloride (0.1g, 170mCi) in methanol (2ml) was treated with diazomethane (approx. 2g) in ether (150 ml) in portions (15ml) during 3h. After 18h the mixture was evaporated, the residue dissolved in a solution of arecoline hydrochloride (5.0g) in IM-HCl (lOml) and the solution evaporated to dryness in vacuo. The residue was recrystallized from propan-l-ol to constant radioactivity to yield colourless needles (4.6g; sp. radioactivity 1.72 Ci/mol) of [3H]arecoline hydrochloride, m.p. and mixed m.p. with the unlabelled compound, 158°C. Chromatography in solvents (a), (b), (d) and (e) showed that the compound was indistinguishable from arecoline hydrochloride.
1,2,5,6-Tetrahydro-1 -methylnicotinic acid methyl ester 1-oxide (arecoline 1-oxide, III, Scheme 1). A solution of arecoline (12.2g, 0.08mol) in ether (50ml) was stirred at 0°C and treated with aq. 33% (w/v) peroxyacetic acid (22.8g, approx. 0.1mol) dropwise during 30min. After 2 h the oily lower layer which separated was dissolved in ethanol and precipitated three times by the addition of ether and dried at 65°C/15mmHg over P205 to give arecoline 1-oxide as a pale yellow viscous oil (10.6g, yield 79%) (Found: C, 56.5; H, 7.6; N, 7.8; C8H13NO3 requires C, 56.1; H, 7.65; N, 8.2%). Chromatography in solvents (1.9g, 17.2mCi) in lOM-NaOH (1 ml) at 00C was extracted with chloroform (3x65m); the extracts were combined, dried (over Na2S04) and evaporated; the residue was dissolved in ether (10ml) and treated with 33% peroxyacetic acid(4ml). As described forthe unlabelled analogue, chromatographically homogeneous [3H]arecoline 1-oxide (0.85g; sp. radioactivity, 1.72Ci/mol) was obtained.
1;2-Dihydro-1-methylnicotinic acid methyl ester (VI, Scheme 1). Arecoline 1-oxide (6g) was heated at 140°C for 1 h. The product was cooled and extracted with hot light petroleum:(b.p. .60-80'C) (3 x 20ml). The combined extracts were washed with water (2 x 10 ml), dried (over Na2SO4) and evaporated in vacuo, and the residue was recrystallized from light petroleum (b.p. 60-80'C) to Similar results were obtained from the oxidation of arecoline (1.55g) with aq. 30% (v/v) hydrogen peroxide (5 ml) at 230C for 16h. (1 ml) with 30% hydrogen peroxide (0.5 ml) or with 33% peroxyacetic acid (0.5 ml) at 230C and examination of the mixtures by chromatography in solvent (d) at hourly intervals during 8h revealed that the oxidation of arecaidine proceeded slowly and detectable amounts of arecaidine 1-oxide were formed after 4 h.
RESULTS

Metabolism of [3H]arecoline. [3H]
Arecoline hydrochloride (total dose 40mg, 360,tCi) was administered to four rats and the urine and faeces were collected during 18h. Extraction of the faeces with aq. 80% methanol (2 x 30ml) followed by measurement of radioactivity of the residue obtained after evaporation of the combined extracts revealed that approx. 1.2% of the administered radioactivity was excreted in the faeces; this was not further examined. The glass rods, filter paper and inside of the cage were extracted with aq. 80% methanol in lOOml portions until the final extract contained negligible radioactivity as determined by scintillation counting. The extracts were combined and evaporated to dryness in vacuo, and the residue was dissolved in water (15ml). Measurement of radioactivity of samples (0.l ml) showed that approx. 19.5% of the administered radioactivity was excreted in the urine. The rate of excretion of the remaining radioactivity was not investigated. Samples (0.1 ml) were chromatographed in solvents (a) and (b) on Whatman 3MM chromatography paper and strips (2cm wide and lem along the direction of development) were cut off and assayed for radioactivity. This showed the presence ofsix radioactive peak areas, corresponding to the metabolites shown in Table 1 . The amounts of the metabolites were determined from the radioactivity of each peak area and are expressed as a percentage of the total radioactivity (method A). Metabolites I to V were also determined by isotope-dilution analysis (method B), as follows: a sample (0.5g) of arecoline hydrochloride, arecaidine hydrochloride, arecaidine 1 -oxide chloride or N -acetyl -S -(3-carboxy -1 -methylpiperid-4-yl)-L-cysteine was dissolved in the minimum volume of 0.1 M-hydrochloric acid and treated with the urine concentrate (0.5ml). The mixtures were evaporated to dryness in vacuo and the residues recrystallized to constant radioactivity from propan-l-ol, aq. 80% ethanol, propan-l-ol and ethanol respectively. The chemical purity of each constant-radioactivity product so obtained was checked by mixed-m.p. determinations and by chromatography in solvents (a) and (b); the radiochemical purity was checked by chromatography in solvent (a) followed by determination of radioactivity of the appropriate strip cut [3H]Arecoline 1-oxide (20mg, 180/ACi) was administered to two rats. The urine was collected for 16h and a concentrate was prepared and analysed by method B for the presence of arecoline, arecaidine, arecoline 1-oxide, arecaidine 1-oxide and N-acetyl-S-(3-carboxy-1-methylpiperid-4-yl)-L-cysteine as described for the metabolism of [3H]arecoline.
